SCHEMBL6718324

SCHEMBL6718324

O=S(=O)(Nc1cccc(C2=NCCc3ccc(F)cc32)c1)c1cccc(C(F)(F)F)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
PIK3CB P42338 1/20 0.46
MAP2K4 P45985 2/20 0.46
KMT2A Q03164 2/20 0.45
PTPN2 P17706 2/20 0.44
PTPN1 P18031 2/20 0.44
PTPN5 P54829 2/20 0.44
PKM P14618 1/20 0.44
PKLR P30613 1/20 0.44
CASP3 P42574 1/20 0.44
HSD17B2 P37059 1/20 0.44
LMNA P02545 2/20 0.44
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
IDH2 P48735 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NR3C1 P04150 2/20 0.43
AR P10275 2/20 0.43
HSPD1 P10809 1/20 0.43
HSPE1 P61604 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6720398 0.93 TSHR (0.47) TSHRPIK3CBMAP2K4KMT2APTPN2
SCHEMBL6724650 0.91 PTPN2 (0.48) TSHRPIK3CBMAP2K4PTPN2PTPN1
SCHEMBL6714887 0.89 TSHR (0.50) TSHRPIK3CBKMT2APTPN2PTPN1
SCHEMBL6720500 0.87 TSHR (0.50) TSHRPIK3CBKMT2APTPN2PTPN1
SCHEMBL6716641 0.85 PFKFB3 (0.47) MAP2K4LMNAMAPTCDK1CCNB1
SCHEMBL6724800 0.85 UQCRB (0.47) KMT2ALMNAMEN1MAPTCA1
SCHEMBL6725587 0.84 TSHR (0.47) TSHRPIK3CBKMT2APTPN2PTPN1
SCHEMBL6714954 0.84 THRB (0.50) TSHRPIK3CBMAP2K4PTPN2PTPN1
SCHEMBL6716742 0.84 PFKFB3 (0.48) PIK3CBKMT2APKMPKLRLMNA
SCHEMBL6714868 0.83 CASP3 (0.43) KMT2ACASP3MEN1MAPTFFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6818651-B2 ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE ALTANA PHARMA AG (DE) 2004-11-16 US disclosed
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors ALTANA PHARMA AG (DE) 2004-03-04 US disclosed
EP-1337515-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 2003-08-27 EP disclosed
WO-2002040450-A1 (DIHYDRO)ISOQUINOLINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS ALTANA PHARMA AG (DE) 2002-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044212-A1 (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors PDE7B, PDE3B, PDE3A TSHR 3790/4885PIK3CB 1685/4885MAP2K4 2903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.